Robert Wapenaar

700 total citations
25 papers, 289 citations indexed

About

Robert Wapenaar is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Psychiatry and Mental health. According to data from OpenAlex, Robert Wapenaar has authored 25 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Psychiatry and Mental health. Recurrent topics in Robert Wapenaar's work include Chronic Lymphocytic Leukemia Research (6 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer, Lipids, and Metabolism (4 papers). Robert Wapenaar is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer, Lipids, and Metabolism (4 papers). Robert Wapenaar collaborates with scholars based in Netherlands, Belgium and France. Robert Wapenaar's co-authors include Walter Krause Neto, Liana Gercheva, Rudolf Schlag, Aristoteles Giagounidis, Pierre Fenaux, Αchilles Anagnostopoulos, Uwe Platzbecker, Atanas Radinoff, Anna Potamianou and Katharina S. Götze and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and European Journal of Cancer.

In The Last Decade

Robert Wapenaar

22 papers receiving 284 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Wapenaar Netherlands	8	117	86	81	71	40	25	289
Sara Tinsley United States	12	308 2.6×	187 2.2×	26 0.3×	50 0.7×	10 0.3×	51	497
Razelle Kurzrock United States	6	98 0.8×	53 0.6×	46 0.6×	63 0.9×	14 0.3×	7	403
Sarah N. Gibbs United States	9	41 0.4×	32 0.4×	33 0.4×	21 0.3×	16 0.4×	25	228
Valentina Pierini Italy	11	158 1.4×	63 0.7×	19 0.2×	28 0.4×	4 0.1×	31	484
Huiling Pei United States	11	195 1.7×	37 0.4×	26 0.3×	46 0.6×	39 1.0×	42	620
Uzoma A. Anele United States	13	25 0.2×	66 0.8×	210 2.6×	113 1.6×	5 0.1×	37	561
F. Imbesi Italy	10	14 0.1×	142 1.7×	37 0.5×	41 0.6×	21 0.5×	19	284
Katherine Sear United States	7	53 0.5×	103 1.2×	22 0.3×	67 0.9×	18 0.5×	10	249
Christian Jehn Germany	9	44 0.4×	16 0.2×	40 0.5×	56 0.8×	13 0.3×	16	320
Jennifer Poon United States	10	39 0.3×	67 0.8×	16 0.2×	111 1.6×	4 0.1×	16	278

Countries citing papers authored by Robert Wapenaar

Since Specialization

Citations

This map shows the geographic impact of Robert Wapenaar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Wapenaar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Wapenaar more than expected).

Fields of papers citing papers by Robert Wapenaar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Wapenaar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Wapenaar. The network helps show where Robert Wapenaar may publish in the future.

Co-authorship network of co-authors of Robert Wapenaar

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Wapenaar. A scholar is included among the top collaborators of Robert Wapenaar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Wapenaar. Robert Wapenaar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Puig, L., Antonio Costanzo, E.M.G.J. de Jong, et al.. (2024). Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial. Dermatology and Therapy. 14(9). 2539–2558.

Puig, L., Antonio Costanzo, E.M.G.J. de Jong, et al.. (2023). Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial. American Journal of Clinical Dermatology. 25(2). 315–325. 2 indexed citations

Bjartell, Anders, Luís Costa, Gero Kramer, et al.. (2022). Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. European Urology Open Science. 45. 12–22. 7 indexed citations

Dartigeas, Caroline, et al.. (2022). FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL. SHILAP Revista de lepidopterología. 4(3). 65–74. 6 indexed citations

Janssens, Ann, Zwi Berneman, Fritz Offner, et al.. (2022). Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study. SHILAP Revista de lepidopterología. 4(4). 133–143. 5 indexed citations

Mateos, María‐Victoria, Katja Weisel, Valerio De Stefano, et al.. (2021). LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.. Journal of Clinical Oncology. 39(15_suppl). 8041–8041. 4 indexed citations

Bjartell, Anders, Nicolaas Lumen, Pablo Maroto, et al.. (2021). Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. Targeted Oncology. 16(3). 357–367. 11 indexed citations

Janssens, Ann, Sylvia Snauwaert, Dominique Bron, et al.. (2021). EFFECTIVENESS AND SAFETY OF IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL) IN BELGIAN ROUTINE CLINICAL PRACTICE WITH A 3‐YEAR FOLLOW‐UP. Hematological Oncology. 39(S2). 1 indexed citations

Chowdhury, Simon, Anders Bjartell, Nicolaas Lumen, et al.. (2020). Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Targeted Oncology. 15(3). 301–315. 49 indexed citations

10.

Janssens, Ann, et al.. (2019). PF494 CLINICAL OUTCOMES WITH SINGLE‐AGENT IBRUTINIB FOR RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): INTERIM ANALYSIS (IA) OF THE BELGIAN IBRUTINIB REAL‐WORLD DATA (BIRD) STUDY. HemaSphere. 3(S1). 199–200.

11.

Janssens, Ann, et al.. (2019). PF384 EFFECTIVENESS AND SAFETY OF IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN ROUTINE CLINICAL PRACTICE: INTERIM ANALYSIS (IA) OF THE BELGIAN IBRUTINIB REAL-WORLD DATA (BIRD) STUDY. HemaSphere. 3(S1). 144–144. 2 indexed citations

12.

Fenaux, Pierre, Valeria Santini, Maria Antonietta Aloe Spiriti, et al.. (2018). A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 32(12). 2648–2658. 99 indexed citations

13.

Chowdhury, Simon, Alison Birtle, Anders Bjartell, et al.. (2017). Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.. Journal of Clinical Oncology. 35(6_suppl). 212–212. 3 indexed citations

14.

Chowdhury, Simon, Alison Birtle, Anders Bjartell, et al.. (2017). Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.. Journal of Clinical Oncology. 35(15_suppl). 5028–5028. 3 indexed citations

15.

Schreiner, A., et al.. (2014). Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS). The World Journal of Biological Psychiatry. 15(7). 534–545. 19 indexed citations

16.

Schreiner, A., et al.. (2013). 1736 – Long-acting Injectable Risperidone And Oral Antipsychotics In Patients With Schizophrenia - a Prospective One-year Non-interventional Study (inors). European Psychiatry. 28(S1).

17.

Aman, Michael G., Jan K. Buitelaar, Goedele De Smedt, Robert Wapenaar, & Carin Binder. (2005). Pharmacotherapy of Disruptive Behavior and Item Changes on a Standardized Rating Scale: Pooled Analysis of Risperidone Effects in Children with Subaverage IQ. Journal of Child and Adolescent Psychopharmacology. 15(2). 220–232. 8 indexed citations

18.

Majkowski, J, Walter Krause Neto, Robert Wapenaar, & Joop van Oene. (2005). Time Course of Adverse Events in Patients with Localization‐related Epilepsy Receiving Topiramate Added to Carbamazepine. Epilepsia. 46(5). 648–653. 17 indexed citations

19.

Hovens, Johannes E., et al.. (2005). Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. Journal of Psychopharmacology. 19(1). 51–57. 20 indexed citations

20.

Wapenaar, Robert, et al.. (2003). A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurologica Scandinavica. 108(1). 9–15. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact